tumor antigen-sensitized dendritic cell vaccine

A tumor antigen-sensitized dendritic cell (DC) vaccine is a form of personalized immunotherapy in which a patient's own dendritic cells are harvested and then exposed ex vivo to specific tumor antigens. These sensitized DCs are then reintroduced into the patient, where they function as potent antigen-presenting cells (APCs). The goal is to stimulate the patient's immune system—particularly T cells—to recognize and attack cancer cells expressing those antigens. The mechanism involves loading or pulsing DCs with peptides or proteins derived from tumors (including neoantigens), leading to presentation via MHC class I and II molecules, activation of CD8+ cytotoxic T lymphocytes and CD4+ helper T cells, upregulation of co-stimulatory molecules such as CD80/CD86, and secretion of inflammatory cytokines like IL-12 or type I interferons. This approach aims to overcome the natural immune tolerance toward self-antigens that many tumors exploit for immune evasion. Tumor antigen-sensitized DC vaccines have been investigated in various cancers including non-small cell lung cancer (NSCLC), breast cancer, melanoma, prostate cancer, glioblastoma multiforme, among others[1][2][3][4][5]. They are typically administered via intradermal or intratumoral injection.

Other names

tumor antigen-sensitized DC vaccinetumor antigen-loaded dendritic cell vaccineDC-based cancer vaccine